{"disease":{"id":"attention-deficit-disorder","name":"attention deficit disorder"},"drugs":{"marketed":[{"drug_id":"lisdexamfetamine","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyvanse","generic_name":"LISDEXAMFETAMINE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Sodium-dependent dopamine transporter","drug_class":"Central Nervous System Stimulant","quality_score":80,"revenue":"3200","mechanism":"Vyvanse works by blocking the dopamine transporter, allowing more dopamine to be available in the brain."},{"drug_id":"lisdexamfetamine","indication_name":"Attention Deficit Hyperactivity Disorder (ADHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyvanse","generic_name":"LISDEXAMFETAMINE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Sodium-dependent dopamine transporter","drug_class":"Central Nervous System Stimulant","quality_score":80,"revenue":"3200","mechanism":"Vyvanse works by blocking the dopamine transporter, allowing more dopamine to be available in the brain."},{"drug_id":"amfetamine","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amphetamine Sulfate","generic_name":"amfetamine","company_name":"UCB","drug_phase":"marketed","molecular_target":"Sodium-dependent dopamine transporter","drug_class":"Central Nervous System Stimulant","quality_score":66,"revenue":"172.0","mechanism":""},{"drug_id":"methamphetamine","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Desoxyn","generic_name":"METHAMPHETAMINE","company_name":"Ajenat Pharms","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"Amphetamine Anorectic","quality_score":77,"revenue":"172.0","mechanism":"Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity."},{"drug_id":"amphetamine-sulfate","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amphetamine Sulfate","generic_name":"AMPHETAMINE SULFATE","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Sodium-dependent dopamine transporter","drug_class":"Central Nervous System Stimulant","quality_score":10,"revenue":"172.0","mechanism":""},{"drug_id":"dexamfetamine","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xelstrym","generic_name":"dexamfetamine","company_name":"UCB","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":"172.0","mechanism":"Xelstrym works by blocking the reuptake of noradrenaline, allowing it to stay in the brain for longer and increasing alertness and focus."},{"drug_id":"methylphenidate","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ritalin","generic_name":"methylphenidate","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"clonidin","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clonidin","company_name":"Medical University of Vienna","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"concerta","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Concerta","company_name":"Lei Lei, MD","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"mebicar","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adaptol","generic_name":"mebicar","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Adaptol is thought to work by modulating neurotransmitter activity in the brain."},{"drug_id":"strattera","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Strattera","company_name":"University of Oklahoma","drug_phase":"marketed","molecular_target":"Krueppel-like factor 10, Kir3.1/Kir3.4, Kir3.1/Kir3.2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"dextroamphetamine","indication_name":"Attention Deficit Hyperactivity Disorder (ADHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXTROAMPHETAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Dopamine transporter (DAT), Norepinephrine transporter (NET)","drug_class":"Central nervous system stimulant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"guanfacine","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tenex","generic_name":"GUANFACINE","company_name":"Promius Pharma","drug_phase":"marketed","molecular_target":"Nischarin","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":65,"revenue":null,"mechanism":"Tenex works by stimulating alpha-2 adrenergic receptors in the brain, which helps to reduce the activity of certain nerve cells."},{"drug_id":"atomoxetine","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Strattera","generic_name":"ATOMOXETINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"Norepinephrine Reuptake Inhibitor","quality_score":66,"revenue":null,"mechanism":"Strattera works by blocking the reabsorption of norepinephrine in the brain, allowing more of this neurotransmitter to be available for use."},{"drug_id":"serd","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SERD","company_name":"Fudan University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"vyvanse","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vyvanse","company_name":"Vanderbilt University","drug_phase":"marketed","molecular_target":"Sodium-dependent dopamine transporter, Sodium-dependent noradrenaline transporter, Synaptic vesicular amine transporter","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dextroamphetamine-sulfate","indication_name":"Attention Deficit Hyperactivity Disorder (ADHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXTROAMPHETAMINE SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"serdexmethylphenidate","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azstarys","generic_name":"SERDEXMETHYLPHENIDATE","company_name":"Commcave Therapeutics Sa","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Azstarys increases levels of dopamine and norepinephrine in the brain to help regulate attention and impulse control."},{"drug_id":"clonidine","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Catapres-Tts-1","generic_name":"CLONIDINE","company_name":"Lavipharm","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"dexmethylphenidate","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Focalin","generic_name":"DEXMETHYLPHENIDATE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sodium-dependent dopamine transporter","drug_class":"Central Nervous System Stimulant","quality_score":62,"revenue":null,"mechanism":"Focalin works by blocking the dopamine transporter, allowing more dopamine to be available in the brain."},{"drug_id":"pemoline","indication_name":"Attention deficit hyperactivity disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pemolin","generic_name":"PEMOLINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium-dependent dopamine transporter","drug_class":"pemoline","quality_score":21,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":21,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04132557","title":"A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine","phase":"","overall_status":"COMPLETED","enrollment_count":430000,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05206734","title":"Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health","phase":"","overall_status":"COMPLETED","enrollment_count":19469,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT04113551","title":"A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":17418,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT00339729","title":"Johnston County ADHD Study: Environmental, Reporductive, and Familial Risk Factors for Attention-Deficit Hyperactivity Disorder (ADHD)","phase":"","overall_status":"COMPLETED","enrollment_count":8000,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT05442229","title":"A Cross-sectional Study to Evaluate Speech and Language Development in Chinese Children Aged 2-6 Years","phase":"","overall_status":"UNKNOWN","enrollment_count":5744,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05870605","title":"Drug Use Study With Intuniv® in European Countries","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT00001246","title":"Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4274,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT02562248","title":"Improving Anxiety Detection in Pediatrics Using Health Information Technology","phase":"NA","overall_status":"COMPLETED","enrollment_count":3267,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT03233867","title":"A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations","phase":"","overall_status":"COMPLETED","enrollment_count":2503,"lead_sponsor_name":"Aevi Genomic Medicine, LLC, a Cerecor company","has_results":false},{"nct_id":"NCT05137704","title":"A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyperactivity Disorder (ADHD) in Adults in England","phase":"","overall_status":"COMPLETED","enrollment_count":2236,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06848959","title":"Development and Application of a Diagnosis and Treatment System for Children's Brain Diseases Based on Knowledge Graphs and Large Models","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Yun Liu,PhD","has_results":false},{"nct_id":"NCT06668519","title":"Magnetoencephalography in Children","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT00006177","title":"Child & Adolescent Bipolar Disorder Brain Imaging and Treatment Study","phase":"","overall_status":"COMPLETED","enrollment_count":1303,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT00550667","title":"Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood","phase":"","overall_status":"COMPLETED","enrollment_count":1120,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03144739","title":"Collaborative Care for Children's Mental Health Problems","phase":"NA","overall_status":"COMPLETED","enrollment_count":1111,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04631042","title":"Developing Brain, Impulsivity and Compulsivity","phase":"","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT01721720","title":"Genetic, Brain Structure, and Environmental Effects on ADHD","phase":"","overall_status":"COMPLETED","enrollment_count":1091,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT06112483","title":"SWELE Program: An Unstructured Outdoor Play With Mindfulness-based Interventions to Promote Mental Health Among Students With Special Education Needs","phase":"","overall_status":"UNKNOWN","enrollment_count":1064,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT05875363","title":"Neurodevelopmental Disorders in Youth With Criminal Behaviors","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03847402","title":"The Early Integrated Intervention for Child Brain-developmental Disorders in China","phase":"NA","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT04574414","title":"Determining the Impact of Air Pollution on the Developing Brain","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Jagiellonian University","has_results":false},{"nct_id":"NCT01074294","title":"Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":740,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT05279313","title":"A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":680,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT03605849","title":"A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":662,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT03605680","title":"A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":604,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT07495683","title":"Personalizing Psychosocial Intervention for Children With Disruptive Behaviour","phase":"NA","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Centre for Addiction and Mental Health","has_results":false},{"nct_id":"NCT03605836","title":"A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT05780853","title":"A Game-based Neurodevelopmental Assessment for Young Children","phase":"","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"Brightlobe Limited","has_results":false},{"nct_id":"NCT06530758","title":"Does the Format of the Adult ADHD Self-Report Scale Impact the Results","phase":"NA","overall_status":"COMPLETED","enrollment_count":587,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT05428033","title":"A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":574,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT01552902","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT01081145","title":"Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":528,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT00152035","title":"Safety of SPD465 in Treating Adults With ADHD.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":505,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT05802680","title":"Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Texas at Austin","has_results":false},{"nct_id":"NCT01552915","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":464,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT05257265","title":"A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":459,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT04727476","title":"The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders","phase":"","overall_status":"UNKNOWN","enrollment_count":413,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT00152022","title":"Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":412,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT06221358","title":"Pharmacogenomics of Stimulant Treatment Response","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT06019429","title":"Promoting Social-emotional Development and Self-esteem in Primary School Students","phase":"NA","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Universiteit Leiden","has_results":false},{"nct_id":"NCT04085172","title":"A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":396,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT01247610","title":"Adult Outcome of Children With Attention-deficit/Hyperactivity Disorder","phase":"","overall_status":"COMPLETED","enrollment_count":390,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT04016779","title":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":374,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04569357","title":"Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":363,"lead_sponsor_name":"Materia Medica Holding","has_results":true},{"nct_id":"NCT00001206","title":"Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD)","phase":"","overall_status":"COMPLETED","enrollment_count":347,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT00152009","title":"Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":345,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT06808555","title":"Pai.ACT: AI-Driven ACT Chatbot for Mental Health Triage and Service Evaluation","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":340,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT00997984","title":"Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT06194162","title":"Weighted Blankets for Sleep Disturbance Among Children With ADHD","phase":"NA","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"University Hospital Bispebjerg and Frederiksberg","has_results":false},{"nct_id":"NCT01244490","title":"Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":338,"lead_sponsor_name":"Shire","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}